VentriPoint, University of Washington Sign Research and Technology Development Agreement
Projects Focus on Completion of the Congenital Heart Disease Database and the Further Transition of Knowledge and Processes to VentriPoint for the Development of the VentriPoint Diagnostic System
Under the terms of the agreement, the University of Washington will expand its recruitment of leading institutions world-wide to participate in building comprehensive databases of right and left ventricle reconstructions representing specific heart diseases, such as congenital heart disease (CHD). These databases will be referenced by the VDS as it delivers three-dimensional models and analysis of patients' hearts based on anatomical points identified by doctors on two-dimensional scans.
"Our core technology was first developed at the University of Washington, so it makes sense to collaborate with their subject matter experts," said Joseph Ashley, CEO of VentriPoint Diagnostics. "The results of these projects will enhance and speed the commercial development of the VentriPoint Diagnostic System, which uses existing medical imaging systems to generate critical heart measurements in a rapid and inexpensive manner not currently available."
Under the agreement, the University of Washington will collaborate with VentriPoint to increase the size of the database used by the VDS by up to 160 additional CHD heart reconstructions of different conditions. The University of Washington will also continue its transition of knowledge and processes to VentriPoint, in support of the technology license. It will also commence recruitment of patients with pulmonary hypertension to begin development of a subsequent VDS application. Financial terms of the agreement were not disclosed.
Other news from the department science
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.